Cargando…
ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C)
BACKGROUND: Circulating tumour DNA (ctDNA) to detect minimal residual disease (MRD) is emerging as a biomarker to predict recurrence in patients with curatively treated early stage colorectal cancer (CRC). ctDNA risk stratifies patients to guide adjuvant treatment decisions. We are conducting the UK...
Autores principales: | Slater, Susanna, Bryant, Annette, Chen, Hsiang-Chi, Begum, Ruwaida, Rana, Isma, Aresu, Maria, Peckitt, Clare, Zhitkov, Oleg, Lazaro-Alcausi, Retchel, Borja, Victoria, Powell, Rachel, Lowery, David, Hubank, Michael, Rich, Thereasa, Anandappa, Gayathri, Chau, Ian, Starling, Naureen, Cunningham, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026439/ https://www.ncbi.nlm.nih.gov/pubmed/36941575 http://dx.doi.org/10.1186/s12885-023-10699-4 |
Ejemplares similares
-
Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study
por: Turkes, Fiona, et al.
Publicado: (2022) -
Adjuvant chemotherapy for early-stage cervical cancer
por: Asano, Hiroshi, et al.
Publicado: (2016) -
Adjuvant Chemotherapy for Stage III Colon Cancer
por: Taieb, Julien, et al.
Publicado: (2020) -
Adjuvant Chemotherapy for Stage II Colon Cancer
por: Rebuzzi, Sara Elena, et al.
Publicado: (2020) -
Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC
por: Qiu, Bin, et al.
Publicado: (2021)